We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+7.28%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$110M
AUM Growth
-$16.5M
Cap. Flow
-$14M
Cap. Flow %
-12.81%
Top 10 Hldgs %
87.26%
Holding
31
New
11
Increased
5
Reduced
8
Closed
6

Top Buys

1
RVNC
Revance Therapeutics, Inc.
RVNC
+$2.81M
2
ANIK icon
Anika Therapeutics
ANIK
+$2.71M
3
OPTN
OptiNose
OPTN
+$2.62M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$2.59M
5
ACRS icon
Aclaris Therapeutics
ACRS
+$2.26M

Top Sells

1
ADMA icon
ADMA Biologics
ADMA
+$13.1M
2
EOLS icon
Evolus
EOLS
+$12.5M
3
NKTR icon
Nektar Therapeutics
NKTR
+$3.25M
4
CALC icon
CalciMedica
CALC
+$2.17M
5
ALIM
Alimera Sciences
ALIM
+$1.92M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMA icon
1
ADMA Biologics
ADMA
$2.02B
$20.9M 19.07%
1,870,000
-1,556,882
-45% -$13.1M
ALIM
2
DELISTED
Alimera Sciences
ALIM
$19.5M 17.81%
3,511,816
-539,256
-13% -$1.92M
EOLS icon
3
Evolus
EOLS
$377M
$18M 16.41%
1,657,611
-1,016,745
-38% -$12.5M
LKFT
4
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$12M 10.97%
485,000
+91,366
+23% +$2.59M
RVNC
5
DELISTED
Revance Therapeutics, Inc.
RVNC
$7.2M 6.57%
2,800,000
+823,658
+42% +$2.81M
XOMA
6
DELISTED
Xoma
XOMA
$5.93M 5.41%
250,129
-3,641
-1% -$91.1K
ANIK icon
7
Anika Therapeutics
ANIK
$203M
$4.19M 3.82%
165,397
+104,448
+171% +$2.71M
TELA icon
8
TELA Bio
TELA
$32.7M
$2.94M 2.68%
625,645
-62,555
-9% -$330K
RIGL icon
9
Rigel Pharmaceuticals
RIGL
$750M
$2.51M 2.29%
305,000
+200,976
+193% +$2.1M
OPTN
10
DELISTED
OptiNose
OPTN
$2.44M 2.23%
+156,667
New +$2.62M
ACRS icon
11
Aclaris Therapeutics
ACRS
$793M
$2.12M 1.93%
+1,927,446
New +$2.26M
SCPH
12
DELISTED
scPharmaceuticals
SCPH
$1.83M 1.67%
421,703
-25,073
-6% -$110K
AUPH icon
13
Aurinia Pharmaceuticals
AUPH
$2.05B
$1.71M 1.56%
+300,000
New +$1.58M
MIST icon
14
Milestone Pharmaceuticals
MIST
$148M
$1.64M 1.49%
1,239,199
-223,097
-15% -$359K
AYTU icon
15
AYTU BioPharma
AYTU
$23.1M
$1.38M 1.26%
472,469
– –
KPRX icon
16
Kiora Pharmaceuticals
KPRX
$11.7M
$840K 0.77%
+200,000
New +$933K
ACET icon
17
Adicet Bio
ACET
$75.9M
$737K 0.67%
38,090
+29,243
+331% +$784K
SRZN icon
18
Surrozen
SRZN
$255M
$724K 0.66%
+66,084
New +$682K
XGN icon
19
Exagen
XGN
$106M
$653K 0.6%
358,697
-25,903
-7% -$43.9K
KZR
20
DELISTED
Kezar Life Sciences
KZR
$630K 0.58%
+105,045
New +$798K
APRE icon
21
Aprea Therapeutics
APRE
$8.79M
$558K 0.51%
+137,174
New +$707K
TSVT
22
DELISTED
2seventy bio
TSVT
$385K 0.35%
+100,000
New +$451K
ETON icon
23
Eton Pharmaceutcials
ETON
$1.16B
$362K 0.33%
+110,000
New +$385K
IRWD icon
24
Ironwood Pharmaceuticals
IRWD
$635M
$313K 0.29%
+48,012
New +$340K
ACAD icon
25
Acadia Pharmaceuticals
ACAD
$4.38B
$81.3K 0.07%
+5,000
New +$80.7K
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Stonepine Capital Management held 31 positions worth $110M, down 13% from $126M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Stonepine Capital Management withdrew a net $14M in Q2 2024, closing 6 positions and reducing 8 holdings. Its most notable exit was Nektar Therapeutics, an estimated $3.25M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in OptiNose worth $2.44M.

  • Stonepine Capital Management's largest Q2 2024 buy was OptiNose: 156,667 shares worth $2.44M.
  • Stonepine Capital Management added most to Revance Therapeutics, Inc. in Q2 2024, an estimated $2.81M increase.
  • Stonepine Capital Management's biggest Q2 2024 reduction was ADMA Biologics, cutting an estimated $13.1M.
  • Stonepine Capital Management fully exited Nektar Therapeutics in Q2 2024, selling an estimated $3.25M.
  • Stonepine Capital Management's ten largest holdings make up 87% of its $110M portfolio in Q2 2024.
  • Stonepine Capital Management opened 11 new positions and closed 6 in Q2 2024.
  • Stonepine Capital Management's portfolio value fell 13% quarter-over-quarter to $110M.

Based on Stonepine Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.